COVID19 OutcomeS in Myeloma and the Impact of VaCcines
N/A
Completed
NCT05831787
| Condition | Multiple Myeloma |
|---|
| Phase | N/A |
|---|
| Sponsor | ASH Research Collaborative |
|---|
| Status | Completed |
|---|
| Enrollment | 201 participants |
|---|
| Interventions | Patient Reported Outcomes |
|---|
| Start date | Jan 23, 2024 |
|---|
| Completion date | Dec 31, 2024 |
|---|
| Results posted | May 18, 2026 |
|---|
Summary
The COVID-19 pandemic has had an outsized impact on individuals with underlying social and medical vulnerability, leading to increased rates of severe disease, hospitalization, and death in these groups. Participants with underlying immune compromise, such as those with multiple myeloma, represent one such group. The advent of vaccines against SARS-CoV-2 has significantly limited morbidity and mortality across all groups, but the effectiveness of vaccination in individuals who are less likely to mount sufficient antibody response is uncertain. For this reason, booster vaccines have been recommended for those with underlying immune compromise. However, several key gaps remain in our understanding of how to best protect these individuals. There is a dearth of real-world evidence about the effectiveness of vaccination and boosters in patients who are immunocompromised, and very little information specifically about the recently approved mRNA boosters. Additionally, rates of vaccination and booster uptake in the United States remain low. A rapid, decentralized method of ascertaining information related to booster vaccine response and adverse events related to vaccines and COVID-19 infe
Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients.
At Baseline · Participants
| Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease | 196 Participants |
|---|
Feasibility of Obtaining 30-day Clinical and PRO Data Capture From 200 Consented Patients.
30 days after enrollment · Participants
| Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease | 162 Participants |
|---|
Feasibility of Obtaining 6-month Clinical and PRO Data Capture From 200 Consented Patients.
6 months after enrollment · Participants
| Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease | 159 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.